score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		PROS12319B-SU2C-06115114	PROS12319B-SU2C-06115114-Tumor-SM-4W2N9	
Putatively Actionable	Clinical trial			Copy Number	BRCA2	Deletion				0.0	0.0		Putatively Actionable	Olaparib	PARP inhibition	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859													0				BRCA2 Deletion	1.0	PROS12319B-SU2C-06115114	PROS12319B-SU2C-06115114-Tumor-SM-4W2N9	
Putatively Actionable		Clinical evidence		Somatic Variant	AR	Missense	p.L702H	0.5703	128.0	0.0	0.0									Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	21.0	0.7619	0.9998	AR p.L702H (Missense)		PROS12319B-SU2C-06115114	PROS12319B-SU2C-06115114-Tumor-SM-4W2N9	PROS12319B-SU2C-06115114-Normal-SM-4W2NS
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.296						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (30%)		PROS12319B-SU2C-06115114		
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45C	0.45899999999999996	122.0	0.0	0.0																Investigate Actionability	1.0	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324	0	58.0	0.431	1.0	CTNNB1 p.S45C (Missense)		PROS12319B-SU2C-06115114	PROS12319B-SU2C-06115114-Tumor-SM-4W2N9	PROS12319B-SU2C-06115114-Normal-SM-4W2NS
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																					0				ESRP1 Amplification		PROS12319B-SU2C-06115114	PROS12319B-SU2C-06115114-Tumor-SM-4W2N9	
Biologically Relevant				Copy Number	RUNX1T1	Amplification				0.0	0.0																					0				RUNX1T1 Amplification		PROS12319B-SU2C-06115114	PROS12319B-SU2C-06115114-Tumor-SM-4W2N9	
Biologically Relevant				Copy Number	PIK3CB	Amplification				0.0	0.0																					0				PIK3CB Amplification		PROS12319B-SU2C-06115114	PROS12319B-SU2C-06115114-Tumor-SM-4W2N9	
Biologically Relevant				Copy Number	TMPRSS2	Deletion				0.0	0.0																					0				TMPRSS2 Deletion		PROS12319B-SU2C-06115114	PROS12319B-SU2C-06115114-Tumor-SM-4W2N9	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: ESRP1 Amplification, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		PROS12319B-SU2C-06115114		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.252																									0				COSMIC Signature (version 2) 1 (25%)		PROS12319B-SU2C-06115114		
